There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on SAGE Therapeutics (SAGE) and Atara Biotherapeutics (ATRA) with bullish sentiments.
SAGE Therapeutics (SAGE)
In a report released today, Ritu Baral from Cowen & Co. maintained a Buy rating on SAGE Therapeutics, with a price target of $207. The company’s shares opened today at $128.26.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 26.4% and a 48.5% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Allena Pharmaceuticals Inc, and Ionis Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for SAGE Therapeutics with a $219.67 average price target, implying a 71.3% upside from current levels. In a report issued on October 29, Oppenheimer also assigned a Buy rating to the stock with a $170 price target.
.
See today’s analyst top recommended stocks >>
Atara Biotherapeutics (ATRA)
In a report released today, Phil Nadeau from Cowen & Co. maintained a Buy rating on Atara Biotherapeutics. The company’s shares opened today at $36.77.
According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 8.5% and a 50.3% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Alexion Pharmaceuticals.
The the analyst consensus on Atara Biotherapeutics is currently a Moderate Buy rating.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
